• Hyeon Kang Koh, Younghee Park, Taeryool Koo, Hae Jin Park, Me Yeon Lee, Ah Ram Chang, Semie Hong, and Hoonsik Bae.
• Department of Radiation Oncology, Konkuk University School of Medicine and Konkuk University Medical Center, Seoul, Republic of Korea.
• Anticancer Res. 2020 Mar 1; 40 (3): 1771-1778.

Background/AimTo validate the effect of treatment intensification on survival in esophageal squamous cell carcinoma (ESCC) patients undergoing definitive concurrent chemoradiotherapy (dCCRT).Patients And MethodsWe reviewed the medical records of 73 ESCC patients who underwent dCCRT between 2006 and 2017 in 3 institutions.ResultsThe median follow-up time was 13.3 months. The median overall survival (OS) and locoregional recurrence-free survival (LRFS) were 13.3 and 11.2 months, respectively. The median radiotherapy dose was 55.8 Gy, and the median biologically effective dose (BED) was 65.8 Gy. Chemotherapy was given in all patients during dCCRT, and adjuvant chemotherapy was administered in 56 patients (76.7%). Adjuvant chemotherapy improved OS (3-year, 24.2% vs. 11.8%, p=0.004). Higher BED ≥70 Gy improved LRFS (3-year, 41.7% vs. 23.6%, p=0.035).ConclusionThe addition of chemotherapy after dCCRT improves OS. A higher radiotherapy dose improved LRFS, but not OS. Adjuvant chemotherapy should be considered after dCCRT for better outcomes.Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

15 keywords...

hide…